about
Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition.Inhibitors of c-Jun N-terminal kinases: an update.c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR.2-(3-{(3R,4R)-4-Methyl-3-[meth-yl(7H-pyrrolo-[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl}oxetan-3-yl)aceto-nitrile monohydrate.New insights into novel inhibitors against deoxyhypusine hydroxylase from plasmodium falciparum: compounds with an iron chelating potential.The chemistry and biology of mycolactones.Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.tert-Butyl N-[(3R,4R)-1-(2-cyano-acet-yl)-4-methyl-piperidin-3-yl]-N-methyl-carbamate.Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.Click Chemistry: Novel Applications in Cell Biology and Drug Discovery.Developing Small-Molecule Inhibitors of HECT-Type Ubiquitin Ligases for Therapeutic Applications: Challenges and OpportunitiesDevelopment, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine ScaffoldEmerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical BiologyConfigurationally Stabilized Analogs of M. ulcerans Exotoxins Mycolactones A and B Reveal the Importance of Side Chain Geometry for Mycolactone Virulence
P50
Q30313903-2D29CCB3-AF3F-4BE8-8F0E-521355B9CF8DQ35228409-FC5F4590-FC73-445F-A695-AD06FB98BF3DQ35432166-A77CBE04-2AB5-4B62-AF82-07ACDC66160FQ38270314-CEA24C85-7D79-4BA0-9906-777FBBBE5087Q38492604-DE31D33C-70F2-4AA4-A9F0-02674F58D6CCQ38606755-0553816C-1418-4C07-AF12-70C4F9A5E423Q38908786-EC837F31-092B-4A4E-929A-809F96330770Q38947778-54A5D4D4-9075-46F8-88A2-A733DF86A70DQ41463987-539E3A0E-A171-4EB5-9A7C-ED8A7F6CAB70Q41469222-2E141770-5263-4CF1-8C23-AE413FB342B0Q41835379-9F8A1D49-D3F3-44F9-B670-D567A63D1112Q42160873-9C1D2D43-6E4F-4F3D-8C07-4CB53FD3DBF2Q45332740-C8A79E7C-BD2C-436D-BEEC-38011F4E1F9BQ50080906-D9C8B8C6-7EBE-477E-B64F-DB2DA055A039Q58837454-1A57960F-3BE8-4208-BF18-875AD953A753Q88933780-5B8D46B3-62D3-42D9-97C5-E3E27982469AQ90631907-54C422EC-B03C-46D6-8DA0-5B782F0C8E7FQ91794612-3DABE9EE-7C21-4807-8648-7C297396DE03
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matthias Gehringer
@ast
Matthias Gehringer
@en
Matthias Gehringer
@es
Matthias Gehringer
@nl
type
label
Matthias Gehringer
@ast
Matthias Gehringer
@en
Matthias Gehringer
@es
Matthias Gehringer
@nl
prefLabel
Matthias Gehringer
@ast
Matthias Gehringer
@en
Matthias Gehringer
@es
Matthias Gehringer
@nl
P106
P1153
55757911500
P21
P31
P496
0000-0003-0163-3419